Table 4.
RR (95% CI) for history of asthma-like symptoms (group 1, n = 154), diagnosis of current asthma (group 2, n = 94), and diagnosis of not current asthma (group 3, n = 60) compared with nonasthmatics (n = 146) by tertiles of phthalate metabolites.
| Outcome group and exposure | MBzP | MnBP | MEP | MEHHP | ||||
|---|---|---|---|---|---|---|---|---|
| Case/control (n) | RR (95% CI) | Case/control (n) | RR (95% CI) | Case/control (n) | RR (95% CI) | Case/control (n) | RR (95% CI) | |
| Group 1 | ||||||||
| 1st tertile | 44/57 | Referent | 46/60 | Referent | 46/52 | Referent | 57/47 | Referent |
| 2nd tertile | 55/47 | 1.25 (0.94, 1.65) | 53/41 | 1.39 (1.06, 1.82)* | 59/42 | 1.33 (1.03, 1.73)* | 46/47 | 0.92 (0.71, 1.20) |
| 3rd tertile | 55/42 | 1.39 (1.05, 1.86)* | 55/45 | 1.44 (1.09, 1.90)* | 49/52 | 1.08 (0.82, 1.42) | 51/52 | 0.97 (0.74, 1.28) |
| Group 2 | ||||||||
| 1st tertile | 25/57 | Referent | 27/60 | Referent | 29/52 | Referent | 34/47 | Referent |
| 2nd tertile | 34/47 | 1.31 (0.87, 1.98) | 38/41 | 1.87 (1.28, 2.67)** | 35/42 | 1.11 (0.97, 1.27) | 27/47 | 0.98 (0.85, 1.12) |
| 3rd tertile | 35/42 | 1.72 (1.15, 2.59)** | 29/45 | 1.78 (1.18, 2.70)** | 30/52 | 1.04 (0.91, 1.19) | 33/52 | 1.03 (0.89, 1.20) |
| Group 3 | ||||||||
| 1st tertile | 19/57 | Referent | 19/60 | Referent | 17/52 | Referent | 23/47 | Referent |
| 2nd tertile | 21/47 | 1.34 (0.80, 2.25) | 15/41 | 1.46 (0.81, 2.65) | 24/42 | 1.15 (0.99, 1.34) | 19/47 | 0.98 (0.84, 1.13) |
| 3rd tertile | 20/42 | 1.44 (0.83, 2.49) | 26/45 | 1.71 (1.02, 2.88)* | 19/52 | 1.04 (0.91, 1.89) | 18/52 | 0.95 (0.82, 1.10) |
| Models compare children in each outcome group with children without history of asthma-like symptoms controlling for maternal asthma, household smoke exposure, maternal prenatal BPA, maternal prenatal demoralization, maternal prenatal specific gravity, and child age (for outcome groups 2 and 3). *p < 0.05. **< 0.01. | ||||||||